Clinical utility of chromogranin a and octreotide in large cell neuro endocrine carcinoma of the uterine corpus
-
- Shohreh Shahabi
- Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, Danbury, CT;
-
- Ilenia Pellicciotta
- Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, Danbury, CT;
-
- June Hou
- Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, the Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York;
-
- Sarah Graceffa
- Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, Danbury, CT;
-
- Gloria S. Huang
- Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, the Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York;
-
- Robert N. Samuelson
- Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, Danbury, CT;
-
- Gary L. Goldberg
- Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, the Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York;
この論文をさがす
説明
<jats:p> Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix. Consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics. </jats:p>
収録刊行物
-
- Rare Tumors
-
Rare Tumors 3 (4), 129-131, 2011-11-01
SAGE Publications
